Exome-wide association study of levodopa-induced dyskinesia in Parkinson’s disease
Abstract Levodopa is the standard long-term dopamine replacement therapy to treat Parkinson’s disease (PD) symptoms. With time, levodopa may induce debilitating dyskinesias (LID), the treatment of which represents a large clinically unmet need. However, time-to-LID onset varies between patients, ref...
Guardado en:
Autores principales: | Eva König, Alessandra Nicoletti, Cristian Pattaro, Grazia Annesi, Roberto Melotti, Alessandro Gialluisi, Christine Schwienbacher, Anne Picard, Hagen Blankenburg, Irene Pichler, Nicola Modugno, Marina Ciullo, Teresa Esposito, Francisco S. Domingues, Andrew A. Hicks, Mario Zappia, Peter P. Pramstaller |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/729fb5b9e7544bd191b10488b78de1e8 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort
por: Antonina Luca, et al.
Publicado: (2021) -
Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments
por: Bargiotas P, et al.
Publicado: (2013) -
Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats
por: Yang X, et al.
Publicado: (2012) -
Effects and molecular mechanism of chitosan-coated levodopa nanoliposomes on behavior of dyskinesia rats
por: Cao,Xuebing, et al.
Publicado: (2016) -
Ranitidine reduced levodopa-induced dyskinesia by remodeling neurochemical changes in hemiparkinsonian model of rats
por: Shi H, et al.
Publicado: (2015)